Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Todos Medical

Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases
Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Partner Content
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Partner Content
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Partner Content
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Partner Content
Todos Medical To Present At The Emerging Growth Conference
Todos Medical To Present At The Emerging Growth Conference
Partner Content
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Partner Content

Todos Medical Recent News

New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Partner Content
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
New York, NY, and Tel Aviv, ISRAEL – April 6, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd.
Partner Content
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
New York, NY, and Tel Aviv, ISRAEL – April 4, 2022 - Todos Medical, Ltd.
Partner Content
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd.
Partner Content
Todos Medical Reports Case Study Of Patient With Long COVID
Todos Medical Reports Case Study Of Patient With Long COVID
New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.
Partner Content
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
New York, NY, and Tel Aviv, ISRAEL – March 27, 2022 - Todos Medical, Ltd.
Partner Content
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Partner Content
Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma
Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma
- Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19 -
Partner Content
Todos Medical To Present At The Emerging Growth Conference
Todos Medical To Present At The Emerging Growth Conference
- Wednesday, March 16, 2022 at 1:30 pm – 2 pm EST -
Partner Content
Abbott Labs Outlook Cools the Omicron Led Testing Boom
Abbott Labs Outlook Cools the Omicron Led Testing Boom
Photo by Adam Nieścioruk on Unsplash
Partner Content
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy
Partner Content
Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Clinical Data will be released Thursday, January 27th, 2022
Partner Content
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
New York, NY, and Tel Aviv, ISRAEL – January 18, 2022 - Todos Medical, Ltd.
Partner Content
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Partner Content
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
“COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” CEO blog released
Partner Content
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called P
Partner Content
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for hospitalized COVID
Partner Content
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
  Provista completed validation for fingerprick At-Home sample collection of blood for the cPass neutralizing antibody test  
Partner Content
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved